CN110840894B - Composite scar-resistant silicone spray and preparation method thereof - Google Patents
Composite scar-resistant silicone spray and preparation method thereof Download PDFInfo
- Publication number
- CN110840894B CN110840894B CN201911319226.7A CN201911319226A CN110840894B CN 110840894 B CN110840894 B CN 110840894B CN 201911319226 A CN201911319226 A CN 201911319226A CN 110840894 B CN110840894 B CN 110840894B
- Authority
- CN
- China
- Prior art keywords
- scar
- silicone
- spray
- minoxidil
- fluorouracil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of medicines, and particularly relates to a compound scar-resistant silicone spray and a preparation method thereof. The raw material components of the spray comprise, by weight: 0.5-3% of minoxidil, 0.2-0.6% of 5-fluorouracil, 6-10% of silicone, 2-6% of humectant, 0.5-2% of bacteriostatic agent and the balance of ethanol. The spray obtained by mixing minoxidil, 5-fluorouracil and silicone has obvious effect on reducing scar tissue formation. Compared with the lack of any one component, the three components are used in a matching way to play a role in synergy, so that the proliferation of skin scar cells can be obviously inhibited, and the scar degree can be effectively reduced.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a compound scar-resistant silicone spray and a preparation method thereof.
Background
The scar is a problem which is often encountered after surgery and trauma, the appearance is influenced slightly, the function is influenced heavily, the prior methods for treating the hypertrophic scar are numerous, and a better recent effect is obtained, but the long-term effect is not satisfactory.
Silicone is an effective method for treating scars, and can form a protective film with high permeability and high air permeability on the surfaces of scars, prevent bacteria from invading and moisture from volatilizing, and moisten and protect the skin. Experiments show that after the silicone is used, the evaporation rate of local surface water is only half of that of normal skin, so that the wound surface keeps an ideal humidity balance, the moisture of the wound surface is favorable for epithelial cell regeneration, and the hydration effect of water accumulated in the epidermal keratinized layer can change the property of scars. However, when silicone is applied, the skin is easily red and swollen and uncomfortable, the effect is slow, the effect is mainly dependent on physical action, and no effective scar inhibiting component exists. Minoxidil is an azacyclo-ethanepyrimidine derivative, and is clinically used for treating hypertension. In recent years, it has been found that it has an anti-hypertensive activity, an anti-fibrotic activity, an activity of stimulating hair growth and an activity of inhibiting collagen synthesis, and can be used for the treatment of scars. 5-fluorouracil is an antimetabolite that effectively inhibits scar formation and is essential for successful surgery. Research shows that 5-fluorouracil can inhibit fibroblast proliferation and activity. The scar-resistant studies of silicone, 5-fluorouracil and minoxidil have been reported, but there is no precedent in the prior art for combining the three.
Disclosure of Invention
The invention aims to provide a silicone spray product containing minoxidil and 5-fluorouracil, which can slowly and continuously release active ingredients of minoxidil and 5-fluorouracil, can play the moisturizing and softening effects of silicone, can be used together to prepare a spray for treating hyperplastic scars, is convenient to use, is safe, does not have side effects, and has wide application prospect and market development prospect.
In order to solve the technical problems, the invention adopts the technical scheme that:
the compound scar-resistant silicone spray comprises the following raw material components in percentage by weight: 0.5-3% of minoxidil, 0.2-0.6% of 5-fluorouracil, 6-10% of silicone, 2-6% of humectant, 0.5-2% of bacteriostatic agent and the balance of ethanol.
Preferably, the compound scar-resistant silicone spray comprises the following raw material components in percentage by weight: 1-2% of minoxidil, 0.3-0.5% of 5-fluorouracil, 7-9% of silicone, 3-5% of humectant, 1-2% of bacteriostatic agent and the balance of ethanol.
Preferably, the compound scar-resistant silicone spray comprises the following raw material components in percentage by weight: 1.5% of minoxidil, 0.4% of 5-fluorouracil, 8% of silicone, 4% of humectant, 1% of bacteriostatic agent and the balance of ethanol.
Preferably, the silicone has a viscosity of 100-.
Preferably, the humectant is selected from at least one of sodium hyaluronate, glycerol, allantoin, propylene glycol, butylene glycol, or betaine.
Preferably, the bacteriostatic agent is selected from at least one of phenoxyethanol, methyl paraben, ethyl paraben or cason.
Furthermore, the invention also provides application of the compound anti-scar silicone spray in preparing a medicinal product for inhibiting skin scar formation.
Further, the invention also provides a preparation method of the compound anti-scar silicone spray, which comprises the following steps: respectively weighing minoxidil, 5-fluorouracil, silicone, humectant, bacteriostatic agent and a proper amount of ethanol according to the weight ratio, mixing and stirring until the minoxidil, the 5-fluorouracil, the silicone, the humectant, the bacteriostatic agent and the proper amount of ethanol are completely dissolved, and adding the residual ethanol to a specified amount; standing the obtained liquid medicine, filtering, filling into a spray container which is pre-filled with nitrogen, and sealing to obtain the compound scar-resistant silicone spray.
Hypertrophic scars are the result of abnormal wound healing process and are mainly characterized by the vigorous proliferation of fibroblast cells and the massive deposition of collagen. Current research shows that in hypertrophic scar fibroblasts, the concentration of free radicals is higher than that of normal tissues, and the excessive generation and accumulation of the free radicals in local parts are one of the important reasons. Minoxidil is an azacyclo-ethanepyrimidine derivative, and is used for treating hypertension, and has anti-fibrosis and hair growth stimulating effects. Minoxidil has been reported as an anti-fibrotic drug, and the action mechanism of minoxidil is inhibition of fibroblast lysyl hydroxylase activity; because the activity of the lysyl hydroxylase is inhibited, the content of hydroxylysine in a collagen peptide chain is reduced, the cross-linking of collagen is prevented, and the stability of the collagen is reduced, thereby inhibiting the synthesis of the collagen. According to research, 0.25mmol/L-2.0mmol/L minoxidil has an inhibiting effect on proliferation of hypertrophic scar fibroblasts, and intracellular superoxide dismutase is reduced. Therefore, the minoxidil has an inhibiting effect on proliferation of hypertrophic scar fibroblasts, and free radicals of the minoxidil are reduced through superoxide dismutase to play a role.
5-fluorouracil is an antitumor drug. 5-fluorouracil is first converted in vivo to fluorouracil nucleosides and deoxynucleosides, the latter being catalyzed by deoxynucleoside kinases to become nucleotides, accepting a methyl group to form deoxynucleotides. Nucleotides can form covalent bonds with the active center of the enzyme, and DNA synthesis is hindered due to deoxynucleotide deficiency, so that protein synthesis is affected, and therefore collagen synthesis is affected. Some scholars individually apply 5-fluorouracil to treat scars with the concentration of 50mg/ml to obtain certain curative effect, but injection of high-concentration 5-fluorouracil can cause massive necrosis of tissues and initiate a new scar healing process.
Silicones, also known as polysiloxanes or organosilicon polymers, are a class of silicon-containing organic compounds that contain repeating Si — O bonds as the backbone in their chemical structure, with organic groups directly attached to the silicon atoms. The difference of organic groups determines the difference of physical and chemical properties and types of silicone, so that the silicone has wide application in a plurality of fields, and most of medical silicone is polydimethylsiloxane. As the degree of polymerization of the polysiloxane increases, its viscosity also increases, assuming a liquid, gel or solid state. The polysiloxane is colorless, tasteless, odorless, hydrophobic, heat-resistant, antioxidant, insoluble in water and common organic solvents, and has stable chemical properties. The main silicone products are silicone oil, silicone gel, silicone rubber, silicone resin and the like. The therapeutic effect of scars is related to the moisture content of the skin environment at the time of treatment. When the silicone dressing is covered on the surface of the scar, the water evaporation rate of the scar part is half of that of normal skin, the water in the scar is transferred to the horny layer, the water accumulation effect is generated on the horny layer, the proliferation of fibroblasts and the deposition of collagen are inhibited, and the aim of treating the scar is achieved. The continuous application and the increase of the negative electrostatic field have been found by the scholars to accelerate the healing of the scar, so the static electricity generated by the friction between the silicone dressing and the skin is considered to be one of the reasons that the silicone dressing can treat the scar. In addition, clinical observations have shown that the silicone oil component in silicone gel can promote scar softening and accelerate epithelialization.
The invention provides application of a compound anti-scar silicone spray in preparing a medical product for inhibiting skin scar formation, wherein the medical product can inhibit scar generation caused by various types of wounds and promote wound healing, and the wounds and the injuries comprise trauma, mechanical injury, surgical operation, cosmetic operation, burn and scald, frostbite, thermal or chemical burn, abrasion, laceration, blister or erosion caused by radiation and the like.
Compared with the prior art, the invention has the beneficial effects that: the percutaneous absorption of minoxidil and 5-fluorouracil is a complex process, and the drug is separated from the matrix, penetrates through the epidermis and is absorbed into the blood to produce the effect. The transdermal administration of minoxidil and 5-fluorouracil can generate drug effect on local skin, which can not only avoid the damage of liver and gastrointestinal enzymolysis to the drug, but also maintain stable drug concentration on local part for a long time. The silicone spray is a stable excipient, and can effectively fix the minoxidil and the 5-fluorouracil and enable the minoxidil and the 5-fluorouracil to act on scar tissues for a long time. Scar tissue has more new blood vessels and poorer skin barrier function than normal skin, so that the percutaneous absorption function of the minoxidil and the 5-fluorouracil is stronger. By comparative testing, it was surprisingly found that a spray obtained by mixing minoxidil, 5-fluorouracil and silicone had a significant effect on reducing scar tissue formation. Compared with the lack of any one component, the three components are used in a matching way to play a role in synergy, so that the proliferation of skin scar cells can be obviously inhibited, and the scar degree can be effectively reduced.
Detailed Description
The technical solutions in the embodiments of the present invention are clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention. The materials, reagents and the like used are, unless otherwise specified, commercially available reagents and materials.
Example 1
The compound scar-resistant silicone spray comprises the following raw material components in percentage by weight: 2% of minoxidil, 0.3% of 5-fluorouracil, 7% of silicone, 1.5% of sodium hyaluronate, 1.5% of allantoin, 1% of phenoxyethanol and the balance of ethanol.
The silicone was purchased from Shanghai resin works, Inc. and had a number average molecular weight of 2000 and a viscosity of 3000cp at 25 ℃.
The preparation method of the compound scar-resistant silicone spray comprises the following steps: respectively weighing minoxidil, silicone, humectant, bacteriostatic agent and a proper amount of ethanol according to the weight ratio, mixing and stirring until the minoxidil, the silicone, the humectant, the bacteriostatic agent and the proper amount of ethanol are completely dissolved, and adding the residual ethanol to a specified amount; standing the obtained liquid medicine, filtering, filling into a spray container which is pre-filled with nitrogen, and sealing to obtain the compound scar-resistant silicone spray.
Example 2
The compound scar-resistant silicone spray comprises the following raw material components in percentage by weight: 3% of minoxidil, 0.6% of 5-fluorouracil, 9% of silicone, 2% of glycerol, 3% of propylene glycol, 1.5% of methylparaben and the balance of ethanol.
The silicone type and the preparation method of the composite scar-resistant silicone spray are the same as in example 1.
Example 3
The compound scar-resistant silicone spray comprises the following raw material components in percentage by weight: 1.5% of minoxidil, 0.4% of 5-fluorouracil, 8% of silicone, 2% of butanediol, 2% of betaine, 1% of cason and the balance of ethanol.
The silicone type and the preparation method of the composite scar-resistant silicone spray are the same as in example 1.
Comparative example 1
The spray comprises the following raw material components in percentage by weight: 1.9% of 5-fluorouracil, 8% of silicone, 2% of butanediol, 2% of betaine, 1% of cason and the balance of ethanol.
The preparation method of the spray is the same as that of example 1.
Comparative example 2
The spray comprises the following raw material components in percentage by weight: 1.9% of minoxidil, 8% of silicone, 2% of butanediol, 2% of betaine, 1% of cason and the balance of ethanol.
The preparation method of the spray is the same as that of example 1.
Comparative example 3
The spray comprises the following raw material components in percentage by weight: 1.5% of minoxidil, 0.4% of 5-fluorouracil, 8% of polyvinylpyrrolidone, 2% of butanediol, 2% of betaine, 1% of cason and the balance of ethanol.
The preparation method of the spray is the same as that of example 1.
The observation of the curative effect of the compound scar-resistant silicone spray on the treatment of the hyperplastic scar of rabbit ears
1. Experimental animal and rabbit ear scar model establishment
105 Japanese big-ear white rabbits with intact ears, age of 10-12 months and weight of about 2.5kg are selected. According to the conventional establishment and design method of the rabbit ear scar model, scar formation can be seen in the 4 th week after operation, and scar tissues do not exceed the operation area.
2. Animal grouping, administration method and specimen processing
The 105 rabbit ear scar models were divided into 7 groups of 15 animals each. Examples 1-3 correspond to A, B, C groups, comparative examples 1-3 correspond to D, E, F groups, and group G corresponds to a blank control group.
After the ear scars of the 28 th rabbit after the operation are formed, the scar surface of 30 ears of 15 rabbits in the A group is sprayed on the surface of the wound of the example 1Spray mist Agent for treating cancerSpraying was carried out 4 times per day with 6-hour intervals. The treatment method of groups B-F is the same as that of group A. Group G did not do anything.
On the 50 th day of the experiment, the rabbit was killed by air embolism, and the rabbit ear specimen was cut under aseptic condition with part of normal soft skin tissue and perichondrium around the scar. Fixing the specimen in 10% formaldehyde solution, embedding with paraffin, and sending to pathology department for HE staining.
3. Observation index
(1) And (3) histological observation: the appearance of the wound surface, the condition of an operation area, the color, the texture, the size, the thickness and the like of scar tissues are observed every day by adopting a Winghua scar scoring standard, the healing condition of the wound surface and the formation condition of scars are recorded every day, and the change of each group such as the color, the texture, the size and the like after the medicine is taken.
(2) Scar proliferation index HI: and calculating according to the formula HI as A/B, wherein A is the vertical distance from the highest point of the scar bulge to the cartilage surface of the rabbit ear, and B is the vertical distance from the normal skin edge at the periphery of the scar to the cartilage surface of the rabbit ear.
(3) Fibroblast count FBI: firstly, searching a region which is clearly displayed in an HE staining specimen and has the largest number of fibroblasts under a low power microscope, then observing and counting 4 different regions under a high power microscope, and taking the average number of the results, wherein the average number is the number of the fibroblasts of the experimental animal.
4. The statistical method comprises the following steps: statistical analysis was performed using SPSS18.0 software.
5. The treatment results are shown in tables 1-3.
TABLE 1 histological observations
TABLE 2 scar Hyperplasia Index (HI)
TABLE 3 fibroblast count (FBI)
The test results in tables 1-3 show that the compound scar-resistant silicone spray has an obvious inhibition effect on scar hyperplasia of rabbit ears, can obviously reduce the scar area, height, texture, color and plaque volume, effectively inhibits the fibroblast hyperplasia of scar tissues, and obviously degrades collagen fibers in the hyperplastic scar tissues of the rabbit ears. Through comparative experiments, the spray prepared by mixing minoxidil, 5-fluorouracil and silicone has obvious effect on reducing the formation of scar tissues. Compared with the lack of any one component, the three components are used in a matching way to play a role in synergy, so that the proliferation of skin scar cells can be obviously inhibited, and the scar degree can be effectively reduced. The compound scar-resistant silicone spray can form a high-permeability and high-breathability protective film on the surface of a scar, effectively prevent microorganism invasion and water volatilization, play a moistening and protecting role on the skin, promote the metabolism of epithelial histiocytes of the skin, and achieve the purposes of inhibiting the growth of hyperplastic scars and changing the structure of scar tissues. The compound scar-resistant silicone spray is reasonable in compatibility, safe to use and wide in market application prospect.
While embodiments of the invention have been disclosed above, it is not limited to the applications listed in the description and the embodiments, which are fully applicable in all kinds of fields of application of the invention, and further modifications may readily be effected by those skilled in the art, so that the invention is not limited to the specific details without departing from the general concept defined by the claims and the scope of equivalents.
Claims (8)
1. The compound scar-resistant silicone spray is characterized by comprising the following raw material components in percentage by weight: 0.5-3% of minoxidil, 0.2-0.6% of 5-fluorouracil, 6-10% of silicone, 2-6% of humectant, 0.5-2% of bacteriostatic agent and the balance of ethanol.
2. The compound anti-scar silicone spray according to claim 1, is characterized by comprising the following raw material components in percentage by weight: 1-2% of minoxidil, 0.3-0.5% of 5-fluorouracil, 7-9% of silicone, 3-5% of humectant, 1-2% of bacteriostatic agent and the balance of ethanol.
3. The compound scar-resistant silicone spray according to claim 2, is characterized by comprising the following raw material components in percentage by weight: 1.5% of minoxidil, 0.4% of 5-fluorouracil, 8% of silicone, 4% of humectant, 1% of bacteriostatic agent and the balance of ethanol.
4. The composite scar-resistant silicone spray as claimed in any one of claims 1 to 3, wherein the silicone has a viscosity of 100-.
5. The composite scar-resistant silicone spray according to any one of claims 1 to 3, wherein the moisturizer is selected from at least one of sodium hyaluronate, glycerin, allantoin, propylene glycol, butylene glycol, or betaine.
6. The compound scar-resistant silicone spray according to any one of claims 1 to 3, wherein the bacteriostatic agent is at least one of phenoxyethanol, methyl paraben, ethyl paraben or cason.
7. Use of the composite anti-scarring silicone spray of any one of claims 1 to 6 in the manufacture of a pharmaceutical product for inhibiting scarring of the skin.
8. The method for preparing the compound scar-resistant silicone spray according to any one of claims 1 to 6, characterized by comprising the following steps: respectively weighing minoxidil, 5-fluorouracil, silicone, humectant, bacteriostatic agent and a proper amount of ethanol according to the weight ratio, mixing and stirring until the minoxidil, the 5-fluorouracil, the silicone, the humectant, the bacteriostatic agent and the proper amount of ethanol are completely dissolved, and adding the residual ethanol to a specified amount; standing the obtained liquid medicine, filtering, filling into a spray container which is pre-filled with nitrogen, and sealing to obtain the compound scar-resistant silicone spray.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911319226.7A CN110840894B (en) | 2019-12-19 | 2019-12-19 | Composite scar-resistant silicone spray and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911319226.7A CN110840894B (en) | 2019-12-19 | 2019-12-19 | Composite scar-resistant silicone spray and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110840894A CN110840894A (en) | 2020-02-28 |
| CN110840894B true CN110840894B (en) | 2020-06-02 |
Family
ID=69610351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911319226.7A Active CN110840894B (en) | 2019-12-19 | 2019-12-19 | Composite scar-resistant silicone spray and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840894B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1239657A (en) * | 1998-06-24 | 1999-12-29 | 凌沛学 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
| CN1956718A (en) * | 2004-03-22 | 2007-05-02 | 细胞基因公司 | Compositions comprising immunomodulatory compounds for the treatment and management of skin diseases and disorders, and method of using the same |
| EP2586457A1 (en) * | 2011-10-31 | 2013-05-01 | Ludwig-Maximilians-Universität München | S 100 Family proteins and their uses |
| CN103635197A (en) * | 2011-02-02 | 2014-03-12 | 埃克斯利尔德生物制药公司 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) |
| CN104968319A (en) * | 2012-12-11 | 2015-10-07 | Elc管理有限责任公司 | Cosmetic compositions with near infra-red (NIR) light-emitting material and methods therefor |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110105996A1 (en) * | 2009-10-16 | 2011-05-05 | Northwestern University | Methods for scar prevention |
-
2019
- 2019-12-19 CN CN201911319226.7A patent/CN110840894B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1239657A (en) * | 1998-06-24 | 1999-12-29 | 凌沛学 | Antisticking particle and powder containing sodium hyaluronate and their preparation process |
| CN1956718A (en) * | 2004-03-22 | 2007-05-02 | 细胞基因公司 | Compositions comprising immunomodulatory compounds for the treatment and management of skin diseases and disorders, and method of using the same |
| CN103635197A (en) * | 2011-02-02 | 2014-03-12 | 埃克斯利尔德生物制药公司 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF) |
| EP2586457A1 (en) * | 2011-10-31 | 2013-05-01 | Ludwig-Maximilians-Universität München | S 100 Family proteins and their uses |
| CN104968319A (en) * | 2012-12-11 | 2015-10-07 | Elc管理有限责任公司 | Cosmetic compositions with near infra-red (NIR) light-emitting material and methods therefor |
Non-Patent Citations (1)
| Title |
|---|
| 米诺地尔对增生性瘢痕成纤维细胞增殖的影响;刘忠等;《中国皮肤性病学杂志》;20050930;第19卷(第9期);533-535 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110840894A (en) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104587518A (en) | Hyaluronic acid dressing and preparation method thereof | |
| JP2023552126A (en) | Efficacy promoting composition and its use | |
| US20240167028A1 (en) | Methods of treating osmidrosis | |
| CN114984301B (en) | Antibacterial dressing for promoting wound surface to heal without scars and preparation method thereof | |
| CN108135972B (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| CN106420381A (en) | Novel applications of artemisinin ingredients or composition of artemisinin ingredients in skin care | |
| CN112294666B (en) | Silica gel eye cream with permeation promoting function | |
| CN104780902A (en) | Composition for external use | |
| US20070154532A1 (en) | Compositions comprising vitamins and/or derivatives thereof stablished with olea europea extract and/or ionene polymers | |
| CN113813367A (en) | Composition and preparation method and application thereof | |
| IE911403A1 (en) | Compositions and method for topical treatment of damaged or¹diseased tissue | |
| CN110840894B (en) | Composite scar-resistant silicone spray and preparation method thereof | |
| KR20210096056A (en) | A topical pharmaceutical composition for treating or preventing scar | |
| CN106420399A (en) | Laser cosmetology nursing agent, preparation and use method thereof | |
| CN111214694A (en) | Dressing with functions of stopping bleeding and accelerating wound healing and preparation method thereof | |
| CN110664660A (en) | Scar-resistant composition and preparation method thereof | |
| CN112334142A (en) | Pharmaceutical composition for wound treatment or skin activity comprising beta-glucan, glycine and 4',6, 7-trimethoxyisoflavone | |
| KR101154581B1 (en) | Cosmetic composition for skin moisturizing containing Criste Marine callus culture filtrate | |
| CN110917179B (en) | Scar-resistant silicone gel patch and preparation method thereof | |
| CN111714396A (en) | Composition containing ectoin and application thereof in laser beauty treatment | |
| CN109529025A (en) | A kind of medical cosmetology Special sterilizing liquid | |
| US20240307485A1 (en) | Ws635 uses thereof in medicine | |
| CN118078733A (en) | New rehabilitation liquid gel preparation and preparation method and application thereof | |
| Waggett et al. | Update on Low-Molecular Weight Hyaluronic Acid in Dermatology: A Scoping Review | |
| CN118370718A (en) | Gel composition for promoting wound healing |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211228 Address after: 315324 Building 1, 1000 Tianyuan Avenue, Zhouxiang Town, Cixi City, Ningbo City, Zhejiang Province Patentee after: Zhejiang Yongyu Biotechnology Co.,Ltd. Address before: 325035 Wenzhou City National University Science Park incubator, No. 38 Dongfang South Road, Ouhai District, Wenzhou, Zhejiang Patentee before: THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL University |
|
| TR01 | Transfer of patent right |